Small organic probes as amyloid specific ligands – Past and recent molecular scaffolds  by Nilsson, K. Peter R.
FEBS Letters 583 (2009) 2593–2599journal homepage: www.FEBSLetters .orgMinireview
Small organic probes as amyloid speciﬁc ligands – Past and recent
molecular scaffolds
K. Peter R. Nilsson *
Department of Chemistry, IFM, Linköping University, SE-581 83 Linköping, Sweden
a r t i c l e i n f o a b s t r a c tArticle history:
Received 23 March 2009
Revised 8 April 2009
Accepted 9 April 2009
Available online 17 April 2009






Luminescent conjugated polythiophene0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.04.016
Abbreviations: AFM, atomic force microscopy;
microscopy; NMR, nuclear magnetic resonance; PET,
phy; ThT, Thioﬂavine T; PIB, Pittsburgh Compound
SPECT, single photon emission computed tomography;
polythiophene; PTAA, polythiophene acetic acid
* Fax: +46 13 13 75 68.
E-mail address: petni@ifm.liu.seMolecular probes for selective staining and imaging of protein aggregates, such as amyloid, are
important to advance our understanding of the molecular mechanisms underlying protein misfold-
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normal immunohistochemical reagents, such as antibodies have shown limitation for identifying
protein aggregates both in vitro and in vivo, small organic probes have been utilized as amyloid spe-
ciﬁc markers. In this review, past and recent molecular scaffolds that have been utilized for the
development of small organic amyloid imaging agents are discussed.
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Protein misfolding diseases, also referred to as amyloidoses or
proteinopathies, are diseases of disparate etiologies characterized
by extracellular or intracellular proteinaceous deposits in tissues
and organs [1]. These deposits, termed ‘‘amyloid” or inclusion
bodies, result from misfolding and/or partial unfolding of proteins,
followed by the formation of protein aggregates. At least 25 differ-
ent proteins have been reported to form disease-associated amy-
loid in vivo [1], and there is evidence that any given polypeptide
can be induced to form amyloid in vitro under appropriate condi-
tions [2]. From a biophysical perspective, amyloid deposits consist
of ﬁbrils with a diameter of 7–10 nm. These ﬁbrils consist of a
number of protoﬁlaments and structural details of the ﬁbril mor-
phology can be visualized by transmission electron microscopy
(TEM) or atomic force microscopy (AFM) [3,4]. Structural studies
of amyloid with high-resolution methods, such as X-ray diffraction,
have shown that the protein or peptide molecules are arranged so
that the polypeptide chain forms b-strands that run perpendicularchemical Societies. Published by E
TEM, transmission electron
positron emission tomogra-
-B; AD, Alzheimer’s disease;
LCP, luminescent conjugatedto the long axis of the ﬁbril, and novel structural insight andmolec-
ular details have been provided by solid-state nuclear magnetic
resonance (NMR) spectroscopy and by single crystal X-ray diffrac-
tion analysis of small amyloid-like peptide fragments [5–8]. A par-
ticularly signiﬁcant characteristic of the structures determined
with these techniques is that they are remarkably similar even
for polypeptides having no sequence homology, suggesting that
many amyloid ﬁbrils share similar core structures. Hence, most
peptides form comparable aggregated b-sheet rich ﬁbrillar assem-
blies, although heterogenic structures for speciﬁc types of ﬁbril can
be observed as the alignment of adjacent strands and the separa-
tion of the sheets might be slightly different due to the speciﬁc nat-
ure of the side-chain packing.
The shape shifting nature of proteins or peptides when being
converted to amyloid, i.e. going from a native fold to b-sheet rich
ﬁbrillar assemblies, makes it hard to speciﬁcally identify amyloid
with conventional immunochemical reagents such as antibodies.
Firstly, it is hard to separate the aggregated form of the protein
from the native protein as most antibodies recognize a speciﬁc
sequence of a distinct protein independently of the fold of the
protein. Secondly, most antibodies poorly enter the compact
beta-sheet accumulations of amyloid and many amyloids also
incorporate immunoglobulins and complement-derived opsonins.
Hence, antibodies can give rise to both false-negative and false-
positive stains, leading to misdiagnoses of amyloidoses [9,10].
However, conformational antibodies speciﬁc for a diversity of
aggregated states of proteins, including soluble amyloid oligomers,lsevier B.V. All rights reserved.
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[11–14]. Such conformational speciﬁc antibodies show great
promise for being used in clinical diagnostics of amyloidoses and
for studying the underlying molecular and pathological events of
these diseases.
A second class of molecules that can be used for visualization
and identiﬁcation of protein deposits is small hydrophobic agents.
The most common small amyloid ligands are derivatives of Congo
red or Thioﬂavins and in contrast to antibodies these dyes do not
bind to speciﬁc proteins but are rather selective for protein aggre-
gates having an extensive cross b-pleated sheet conformation and
sufﬁcient structural regularity. Molecular scaffold based on these
conventional amyloid ligands will be described in more detail in
the following section. In addition, a novel class of amyloid imaging
agents, luminescent conjugated polythiophenes (LCPs), will also be
discussed in more detail, as these novel dyes seems to identify and
differentiate a broader subset of protein aggregates than conven-
tional dyes.2. Conventional amyloid ligands
Congo red (Fig. 1), an aromatic sulfonated azo dye, was intro-
duced more then 80 years ago and its gold-green birefringence un-
der polarized light has been the gold standard for amyloid
detection ever since [15,16]. Nowadays, a large number of amyloid
ligands have been synthesized and most of these agents are deriv-
atives of Congo red or Thioﬂavine. As shown by Klunk and
co-workers, the key structural feature of Congo red might be the
two acidic functional groups and the spacing between them [17].
Chrysamine G (Fig. 1), a lipophilic analogue of Congo red which
also has two acidic functional groups with the same amount of
spacing between them as seen for Congo red, has also shown high
binding afﬁnity to protein aggregates [18]. Chrysamine G has also
been evaluated for in vivo imaging of amyloid but brain uptake of
the compound in mice was limited [19]. As a consequence, consid-
erable efforts to develop novel derivatives with high blood–brain-
barrier permeability based on the Chrysamine G or Congo red scaf-
folds have been made. In this regard, Methoxy-X04 (Fig. 1), an opti-
mized Chrysamine G derivative which lacks the carboxylic acidFig. 1. Examples of different amyloid imaging agents. Molecular scaffolds generate from
scaffolds (right panel).groups, has proven to be a good candidate for performing in vivo
imaging of protein aggregates in transgenic mouse models by mul-
tiphoton microscopy [20]. Removing the carboxylic acid groups
had little effect on the binding afﬁnity for the protein aggregates,
showing that the planar hydrophobic backbone is crucial for bind-
ing to amyloid. Furthermore, the brain uptake of [11C]MeO-X-04
was shown to be sevenfold higher than that of the related carbox-
ylic acid derivative Me-X-34 [20]. However, the level of brain up-
take of [11C]Me-X04 was still insufﬁcient for using the ligand in
positron emission tomography (PET) studies in humans. Hence,
Congo red and Chrysamine G derivatives have shown to be less
than ideal from a clinical perspective and further optimization of
these derivatives is limited, as the molecular frameworks of these
dyes are rather rigid. As a consequence, recent research has shifted
towards the utilization of other types of molecular frameworks for
the development of amyloid imaging agents.
Thioﬂavine T (ThT, Fig. 1) and Thioﬂavine S (ThS) are other
organic dyes often used for in vitro characterization of amyloid
ﬁbril formation or histopathological staining of amyloid plaques
[21,22]. Although ThT contains a positively charged benzothiazoli-
um unit, whose ionic charge is unfavorable for brain uptake, several
amyloid imaging agent utilizing ThT as a scaffold have been devel-
oped. Klunk and co-workers developed a series of neutral ThT deriv-
atives containing uncharged benzothiazole instead of
benzothiazolium for PET imaging [23–25]. All of these neutral
derivatives showed higher binding afﬁnities towards protein aggre-
gates than the charged compound ThT. One of these compounds,
Pittsburgh Compound-B (PIB) (Fig. 1), has also been evaluated in
human patients with Alzheimer’s disease (AD) and the results sug-
gested that PET imaging with PIB provides quantitative information
on amyloid deposits in living subjects [25]. Other neutral ThT deriv-
atives for single photon emission computed tomography (SPECT)
imaging have also been developed by Kung and co-workers (TZDM,
Fig. 1) [26]. These derivatives showed speciﬁc binding to protein
aggregates at subnanomolar concentrations and this study also in-
cluded iodinated analogues based on the Chrysamine G scaffold
[26]. The same research group has also continued to develop a vari-
ety of ThT derivatives where the benzothiazolium is replaced with
benzoxazole [27], benzofuran [28] or imidazopyridine (IMPY, Fig. 1)
[29].Congo red (left panel), Thioﬂavine T (middle panel) and miscellaneous molecular
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tioned above, other chemical scaffolds have been utilized for the
development of amyloid speciﬁc ligands [30]. Kung and co-workers
have reported novel amyloid ligands based on a stilbene scaffold
(m-I-stilbene, Fig. 1) that could be used for visualization of protein
aggregates with PET or SPECT imaging [31–33]. Furthermore,
vinylbenzoxazole derivatives were recently reported as promising
candidates for imaging of amyloid [34,35]. These derivatives
resemble both ThT and stilbene amyloid ligands as they contain
not only a benzoazole and an aromatic ring in their structures
(ThT derivatives), but also a double bond between them (stilbene
derivatives). One of the amyloid ligands reported, [11C]BF-227
(Fig. 1), demonstrated high binding afﬁnities for protein aggre-
gates, excellent brain penetration and rapid clearance from the
brain, suggesting that this amyloid ligand may be a promising can-
didate for use in clinical diagnostics of proteinopathies [35]. A ﬂuo-
rinated derivative of 2-(1-(6-(dimethylamino)naphthalen-2-
yl)ethylidene) malononitrile ([18F]FDDNP, Fig. 1) has also been
shown to be a promising PET radioligand for imaging AD brain
pathology [36]. The binding afﬁnity of this compound to protein
aggregates was also excellent and competition assays with other
conventional amyloid ligands indicated that the binding site for
FDDNP on protein aggregates was different from those of Congo
red and ThT. However, this indication of a high afﬁnity binding site
separated from ThT has been contradicted by three subsequent
studies [37–39]. Furthermore, a variety of molecular frameworks,
including derivatives of ﬂuorene, biphenyl thiophene, and biphe-
nyltriene, have also been utilized for the development of amyloid
imaging agents [30]. Interestingly, a novel attractive molecular
scaffold including two thiophene moieties were recently reported
and these amyloid imaging ligands were designed for use in near
infra red ﬂuorescent imaging of protein aggregates [40,41]. Indeed,
molecular scaffolds consisting of repetitive thiophene moieties
seem to have an excellent afﬁnity for protein aggregates. Speciﬁ-
cally LCPs, have recently proven to be a novel interesting class of
ﬂuorescent molecules for investigating protein aggregates and
proteinopathies.3. Luminescent conjugated polythiophenes (LCPs)
Electro- and optically active conjugated polymers are a class of
molecules that has been utilized for a wide range of applications,
such as solar cells and light emitting diodes. Additionally, the
molecular similarity between conjugated polymers and biological
polymers offer a great possibility to create simple versatile biosen-
sors, as these two classes of molecules are able to form strong com-
plexes with each other due to multiple non-covalent interactions
[42]. Many of these biosensors exploit the conjugated polymer’s
inherent optical properties and to achieve such polymers, e.g. poly-
mers exhibiting ﬂuorescence with high quantum efﬁciency, a poly-
mer backbone consisting of substituted thiophene rings or ﬂuorene
building blocks is preferable.
The optical processes in conjugated polymers are highly inﬂu-
enced by the conformation of the polymer backbone and the sep-
aration and aggregation of polymer chains. The optical
transitions of conjugated polymers are believed to occur on differ-
ent parts of the same polymer chain, intrachain events, or between
adjacent polymer chains, interchain events. The intrachain events
are mainly dependent on the conformation of the polymer back-
bone and the interchain processes occur as nearby polymer chains
come in contact with each other leading to stacking of the aromatic
ring systems, such as the thiophene rings. These phenomena were
recently shown for a LCP (also reported as conjugated polyelectrol-
yes, CPEs) with a zwitter-ionic side chain functionality, POWT [43].
Due to a change of the net charge of the side chain, the conforma-tional freedom of the thiophene backbone was restricted, leading
to different emission proﬁles from the LCP. The same principle
has also been utilized for assigning distinct conformations of syn-
thetic peptides [44]. Nilsson and co-workers used the optical prop-
erties of POWT for spectral discrimination of synthetic peptides
with opposite charge having a random coil conformation or a
four-helix-bundle motif. Hence, the ﬂexible thiophene backbone
was restricted upon binding to a distinct conformational state of
a molecule. The ability to afford an optical ﬁngerprint correspond-
ing to a distinct conformational state of a speciﬁc molecule sets
LCPs apart from conventional ﬂuorescent dyes. Most conventional
techniques are limited by their reliance on detecting a certain bio-
molecule, whereas the LCPs are identifying a speciﬁc structural
motif or a distinct conformational state of a biomolecule. Hence,
the LCPs offer the possibility to monitor the biochemical activity
of biological events on the basis of a structure–function relation-
ship rather than on a molecular basis. The unique conforma-
tional-sensitive optical properties of LCPs have proven to be a
great asset for studying protein misfolding and aggregation, as
binding of LCPs to distinct forms of protein aggregates gives rise
to speciﬁc optical features for the LCPs. This is an improvement
compared to the other small amyloid imaging agents discussed
earlier, as these probes only change in optical feature whether they
are free in solution or upon binding to amyloid ﬁbrils.4. LCPs for exploring protein aggregation and amyloid ﬁbril
formation in vitro
LCPs with their unique structural related optical properties have
proven to be a powerful tool to study amyloid ﬁbrillation events in
vitro. Recently, novel methods for the detection of formation of
amyloid ﬁbrils in bovine insulin and chicken lysozyme based on
conformational changes of the anionic polythiophene derivative,
PTAA (polythiophene acetic acid, Fig. 2), were reported [45].
Depending on the conformation of the protein, different emission
spectra from PTAA were observed. Upon binding to the native
monomeric form of insulin, PTAA emitted light with emission max-
imum of 550 nm, whereas PTAA bound to amyloid ﬁbrils of insulin
emitted light with lower intensity and the emission maximumwas
red-shifted to 580 nm. Hence, a speciﬁc optical ﬁngerprint was
achieved for the b-sheet containing amyloid ﬁbrils. Furthermore,
when plotting the ratio of the intensity of the emitted light at
550 nm and 580 nm, the formation of insulin ﬁbrils could be mon-
itored. The kinetic plot showed a lag phase, followed by a growth
phase and a plateau phase, which are characteristic for the forma-
tion of amyloid ﬁbrils when Congo red absorbance or ThT ﬂuores-
cence are used as the read-out [45]. The detection of insulin ﬁbrils
was also observed by absorption and visual inspection, which
might be useful for the development of simple screening methods
for the detection of amyloid ﬁbrils [45].
Under the conditions used [45], PTAA was interacting with both
the native form of insulin and the ﬁbrillar form of insulin.
Although, these forms were easily distinguished by distinct ﬂuo-
rescent signatures from PTAA, LCPs selective for amyloid ﬁbrils
would be favorable. A second generation of LCPs was recently syn-
thesized by Konradsson and co-workers [46,47]. Except for having
ionic side chain functionalities on all thiophene moieties, these
molecules also include unsubstituted thiophene rings which give
rise to a greater conformational freedom of the polythiophene
backbone (Fig. 2). This molecular scaffold was achieved through
controlled synthesis of a symmetrical trimer building block that
was further assembled through randomized polymerization. Inter-
estingly, the chain length distribution of these randomly polymer-
ized materials was shown to be rather narrow and around 80–90%
of the material had a well-deﬁned chain length [46,47]. A zwitter-
Fig. 2. Chemical structures of luminescent conjugated polythiophenes (LCPs) and examples of their use as amyloid imaging agents. (a) Chemical structures of the ﬁrst
generation (left panel) and second generation (right panel) of LCPs. (b) Spectra of polythiophene acetic acid (PTAA) (left) and tPOWT (right) bound to native insulin (blue) or
insulin amyloid ﬁbrils (red). (c) Spectrum (left) and ﬂuorescence image (right) of PTAA bound to amyloid deposits in tissue samples. Some representative PTAA stained
amyloid deposits are indicated with white arrows. (d) Fluorescence images of prion deposits, CWD (left) and sheep scrapie (right) being stained by PTAA. Some representative
PTAA stained prion deposits are indicated with white arrows.
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crease in the emission intensity and a blue-shift of the emission
maximum to 560 nm upon binding to insulin amyloid ﬁbrils
[46]. The spectrum for PONT mixed with native monomeric insulin
showed a weaker intensity with a maximum at 600 nm and resem-
bled the spectrum for PONT free in solution, indicating that the
interaction between PONT and native insulin was absent. The
kinetics of the amyloid ﬁbrillation was also followed by plotting
the ratio of the intensity of the emitted light at 560 and 600 nm.
Similar to the observations with PTAA, the characteristic three dif-
ferent phases of amyloid ﬁbril formation were seen [46]. The in-
creased amyloid speciﬁcity for the second generation of LCPs was
also conﬁrmed in a recent study comparing the monomer-based
LCPs with their trimer-based counterpart [47]. Hence, by chemical
design of a trimeric thiophene scaffold, LCPs with enhanced dis-
crimination between the amyloid-like ﬁbrillar state and the corre-
sponding native protein was achieved. So far, LCPs have been used
to distinguish between the native form of proteins and the amyloid
ﬁbrillar form of proteins. However, further chemical development
of novel LCPs might offer a novel approach to discriminate be-
tween different conformational structures observed during the
amyloid formation processes.5. LCPs for histological characterization of protein aggregates
including amyloid
As described above, LCPs can be utilized as molecular tools for
studying the amyloid ﬁbril formation in vitro. However, those
in vitro systems only contained the desired molecules. Recent
studies have also shown that LCPs can be used as amyloid speciﬁcdyes for histological staining of tissue sections and that LCPs ap-
pear to provide additional information regarding the pathological
events of proteinopathies, compared to conventional techniques
[48–52].
Nilsson et al. exhibited the proof of concept by utilizing the LCPs
as amyloid speciﬁc dyes in tissue samples [48]. Under distinct con-
ditions PTAA, POMT and PONT (Fig. 2) were shown to selectively
stain a plethora of amyloid deposits in formalin ﬁxed tissue sec-
tions (Fig. 2). The negatively charged PTAA was amyloid speciﬁc
under alkaline (pH 10) staining conditions, whereas the staining
with the cationic and the zwitter-ionic LCPs were performed at
acidic pH (pH 2). All the LCPs stained amyloid deposits associated
with systemic amyloidoses and local amyloidoses, such as Type 2
diabetes and Alzheimer’s disease (AD). Similar to results obtained
on in vitro formed amyloid ﬁbrils [45], PTAA showed a red-shifted
spectrum with a maximum around 580 nm upon binding to amy-
loid deposits, whereas deposits stained by PONT emitted light with
a more green-yellowish hue [46,48]. Hence, upon binding to amy-
loid deposits in tissue samples, the rotational freedom of the thio-
phene rings and the geometry of the thiophene backbone were
restricted, leading to a speciﬁc emission proﬁle from the LCP sim-
ilar to what was observed on pure amyloid ﬁbrils in solution [45–
48]. Furthermore, some results indicated that PTAA emits light of
different colors upon binding to different amyloid subtypes and
that smaller protein deposits that were undetected with conven-
tional dyes was visualized by PTAA [48].
As mentioned, above, the conformational induced change of the
ﬂuorescence is a distinct intrinsic property seen for LCPs that can-
not be achieved by sterically rigid conventional amyloid ligands
based on the molecular scaffold of Congo red or Thioﬂavins. Thus,
LCPs could offer the possibility to obtain a speciﬁc spectroscopic
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the total amount of protein aggregates, heterogenic populations
of speciﬁc protein aggregates could be observed. These assump-
tions have also been veriﬁed with experimental data using trans-
genic mouse model having AD pathology and transgenic mice
infected with distinct prion strains [49–52].
Upon application of several LCPs to transgenic mouse models
having AD pathology, a striking heterogeneity in the characteristic
plaques composed of the A-beta peptide was identiﬁed [49]. LCP
staining of brain tissue sections revealed different sub-populations
of A-beta deposits, observed as protein aggregates with different
colors. The spectral features of LCPs enabled an indirect mapping
of the architecture of individual amyloid deposits, as the different
colors of the LCPs are associated with different conformations of
the polymer backbone [43]. This notion allowed the authors to
hypothesize how senile plaques are formed. Since the interior of
large amyloid deposits seemed disordered compared to the exte-
rior, it appeared plausible that diffuse aggregated A-beta matured
into a rigid plaque exterior [49]. It should however be noted that
very small amyloid deposits in young mice showed a LCP ﬂuores-
cence, indicative of a highly compact ﬁbrillar structure. Hence, it
is equally plausible that A-beta amyloid deposits assemble from
the outside in, i.e. from rigid ﬁbril association forming a disordered
plaque center [49]. Furthermore, PTAA was recently used for spec-
tral separation of A-beta deposits associated with the Swedish/Arc-
tic mutation or only Swedish mutation in the amyloid precursor
protein (APP), indicating that different point mutations of the amy-
loidogenic protein can give rise to distinct morphologies of protein
deposits [51]. Overall, these ﬁndings might lead to novel ways of
diagnosing AD and the LCP technique could provide a new method
for studying the pathology of the disease in a more reﬁned manner.
LCPs might be particularly useful for identifying distinct toxic enti-
ties giving rise to cell death and loss of neurons, or for establishing
a correlation between the type of protein deposits and the severity
of AD. However, further studies of the molecular interaction be-
tween well-characterized in vitro produced protein aggregates
with distinct structures and LCPs will be necessary in order to cor-
relate the spectroscopic read out from the LCP with a distinct
molecular structure of the protein deposit. Although the achieve-
ment of obtaining certain spectroscopic LCP signatures from heter-
ogenic populations of protein aggregates is beneﬁcial compared to
conventional amyloid imaging probes, correlation of the spectro-
scopic signature to a speciﬁc form of the aggregated protein will
be necessary in order to gain novel insight into the pathological
process of the disease. However, the LCPs could be useful for com-
parison of heterogenic protein aggregates in well-deﬁned experi-
mental systems, such as transgenic mouse models.
Heterogenic protein aggregates are also found in other protein-
opathies, such as the infectious prion diseases. Prions can occur as
different strains and the prion strain phenomenon is believed to be
encoded in the tertiary or quaternary structure of the prion aggre-
gates. This belief was also veriﬁed when protein aggregates in
brain sections from mice infected with distinct prion strains were
stained by LCPs [50]. The LCPs bound speciﬁcally to the prion
deposits and different prion strains could be separated due to alter-
native staining patterns of LCPs with distinct ionic side chains. Fur-
thermore, the anionic LCP, PTAA, emitted light of different
wavelengths when bound to protein deposits associated with a dis-
tinct prion strain (Fig. 2). By calculating ratios of the intensity of
the emitted light at certain wavelengths, prion aggregates associ-
ated with distinct prion strains were easily distinguished from
each other, verifying the usefulness of spectral properties of LCPs
for classiﬁcation of protein deposits. The LCP technique was also
recently used for speciﬁc spectral identiﬁcation of protein deposits
seen for a de novo generated prion strain [52]. These protein
deposits were not stained by any of the conventional amyloid li-gands, ThT and Congo red, indicating that LCPs could be used to
identify a subset of protein deposits normally undetectable by con-
ventional methods [52]. Whether this observation was due to an
increased sensitivity of the LCPs compared to other amyloid li-
gands or if LCPs identify a broader range of structurally diverse
protein deposits compared to conventional amyloid dyes has yet
to be clariﬁed.
In the ﬁrst study of prion strains [50], it was also shown that the
optical ﬁngerprint observed for PTTA bound to protein deposits re-
lated to distinct prion strains most likely occurred due to a struc-
tural variance of the protein deposits. By taking recombinant
mouse prion protein (mPrP) and converting it into two different
types of amyloid ﬁbrils by using varying conditions for ﬁbrillation,
Sigurdson et al. were able to show that the emission proﬁle of
PTAA could be used to distinguish these two ﬁbril preparations
[50]. As these two preparations of ﬁbrils were chemically identical,
having the same protein (mPrP) and being dialyzed against the
same buffer, the spectral differences seen for PTAA were most
likely due to structural differences between the ﬁbrils. The same
procedure has also been performed to distinguish A-beta 1–42
amyloid ﬁbrils grown under different conditions in vitro [49] and
amyloid ﬁbrils built from reduced or intact bovine insulin [53].
In these studies, the zwitter-ionic LCP, tPTT [49], or the cationic
LCP, POMT [53], were used, showing that distinct LCPs can be used
to differentiate protein aggregates of diverse origin. Hence, LCPs
have so far been shown to provide indirect structural insights
regarding the morphology of individual protein deposits. Addition-
ally, LCPs could be used as a complementary amyloid imaging
agent for the characterization of protein deposits associated with
individual prion strains [50,52]. These ﬁndings may be of great va-
lue, as phenomena similar to those occurring in prion strains may
be much more frequent than is now appreciated, and may extend
to additional proteinopathies.6. Future prospects of LCPs
Unexpectedly, conjugated polymer materials that originate
from electronics and solar cells have proven useful to gain novel in-
sights into the molecular mechanism of protein aggregation and
the pathology of proteinopathies [54]. Apparently, the unique opti-
cal properties of LCPs will be useful to gain more information
regarding the molecular details of the protein aggregation process
and the pathological events underlying proteinopathies. However,
there is still a great extent of basic research that needs to be per-
formed to take fully advantage of the technique and to develop
LCP based molecular scaffolds that can be used for diagnostic pur-
poses of these diseases.
As the LCPs have proven to stain a greater diversity of protein
aggregates than Thioﬂavine T and Congo red in histological tissue
samples [50,52], the development of LCP based molecular scaffolds
that can be used for in vivo imaging of protein aggregates would be
of great interest. All the previously reported LCPs have a molecular
weight between 1000 and 5000 Da and will not likely cross the
BBB, so chemical design of smaller well-deﬁned oligomeric thio-
phene derivatives are necessary. These dyes could be utilized in
multiphoton imaging applications for in vivo imaging of protein
aggregates, as previously reported LCPs have been shown to work
efﬁciently in this imaging setup [48]. Such molecules will be excel-
lent for monitoring the molecular pathology of protein misfolding
diseases and disease progress upon experimental treatment in
transgenic mouse models. Nevertheless, multiphoton imaging is
not suitable as a clinical diagnostic tool for proteinopathies, so
radiolabeled versions of novel thiophene scaffolds useable for
PET or SPECT will be advantageous. Hence, there are very clear hur-
dles, including radiolabeling strategies, basic toxicological and
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cules will have to pass in order to be useful in the clinical setting.
Future chemical design of novel well-deﬁned oligomeric thio-
phene scaffolds will certainly include combinatorial approaches
for optimizing the thiophene core structure. Such chemical design
may also provide more effective binders for distinct classes of pro-
tein aggregates and LCPs having different and well-deﬁned chain
lengths would also be of interest in order to understand the confor-
mation induced optical properties of the LCPs. A focus must also be
turned to the molecular details regarding the selective binding site
of LCPs to speciﬁc protein aggregates. Therefore, a general under-
standing of photo-physical processes of LCPs and design rules in
the synthesis of LCPs will be important for continued progress in
the development of novel amyloid imaging based on a repetitive
thiophene scaffold.7. Conclusions
As described in this review, a diversity of molecular scaffolds
has been utilized for the development of smart amyloid imaging
agents. However, there is still a need for novel molecular tools,
as many basic scientiﬁc questions regarding the mysterious molec-
ular and pathogenic events of protein misfolding diseases remain
elusive. Secondly, imaging agents for accurate clinical diagnosis
and for following the progression of these diseases are highly rele-
vant, as successful therapeutic solutions are lacking today to a
large extent due to difﬁculties in reliable and relevant quantitative
monitoring methods. Hopefully, the present knowledge about
amyloid imaging agents will lead to the development of novel
smart imaging agents that will solve these issues.Acknowledgements
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